Lung metastases in prostatic carcinoma

Varkarakis, M. J.; Winterberger, Alan R.; Gaeta, John F.; Moore, Robert H.; Murphy, Gerald P.

doi:10.1016/s0090-4295(74)80160-3

Cited by 76 publications

(26 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most important metastatic site of prostate cancer with regard to clinical diagnosis, as is borne out by autopsy findings, is the skeletal system [2,3]. Bone metastases occur primarily in the pelvis, followed in frequency by the lumbar region of the spine, femurs, thoracic region of the spine, and ribs [ l ] .…”

Section: Lntroducti Onmentioning

confidence: 99%

An assessment of bone scans for monitoring osseous metastases in patients being treated for prostate carcinoma

et al. 1980

View full text Add to dashboard Cite

The National Prostatic Cancer Project held a workshop in March 1980 to examine procedures used to evaluate bone metastases. Variations in techniques used by each of 9 treatment centers, as well as the National Cancer Institute, were compared. One center in particular had developed procedures for quantitating bone scans in addition to the customary qualitative evaluation. Changes in bone scan assessments were also related to changing levels of isoenzymes of acid and alkaline phosphatase. Most consistently correlated with disease changes were prostatic acid phosphatase, as determined by counter-immunoelectrophoresis, and the isoenzyme of bone alkaline phosphatase. Gamma cameras were recommended over rectilnear scanners as were multiple spot films to concentrate on problem areas. Bone scans must be performed prior to therapy and for best assessment no sooner than 3 months to avoid the flair phenomenon. Consistency of both machine settings and patient position are paramount, as are quality of equipment and review of past scans and X-ray films where appropriate to obtain the best assessment of disease status.

show abstract

Section: Lntroducti Onmentioning

confidence: 99%

An assessment of bone scans for monitoring osseous metastases in patients being treated for prostate carcinoma

et al. 1980

View full text Add to dashboard Cite

show abstract

“…The reported incidence of clinically apparent pulmonary metastases is 5 -27% at initial diagnosis, 19,20 whereas autopsy rates show an incidence of between 23 and 74%. 16 -18 In our study, pulmonary metastases had already developed in 20 of 152 (13%) patients at initial diagnosis and in 38 of 60 (63%) at cancer-death, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Varkarakis et al reported that endocrine therapy failed to improve pulmonary metastases in 13 of 14 patients with metastatic PCa. 19 On the other hand, Fabozzi et al showed that endocrine therapy improved the radiographic appearance of pulmonary metastatic lesions in 13 (76.5%) of 17 patients who received no therapy before the development of pulmonary metastases. 20 Thus, the clinical impact of pulmonary metastases in the management of PCa remains obscure.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of pulmonary metastases in stage D2 prostate cancer patients

Nakamachi

Suzuki

Akakura

et al. 2002

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Several prognostic factors such as the extent of bone metastases (EOD) in advanced prostate cancer (PCa) have been reported. Metastasis of the lung is rarely a significant clinical factor in the management of prostate cancer. The present study evaluates the clinical significance of lung metastases. We retrospectively reviewed the PCa database to identify patients with pulmonary metastases at initial diagnosis. The medical records of the patients were examined with respect to age, histologic grade, EOD score, marker response to endocrine therapy and clinical outcome. We then compared several potential clinical factors between patients with and without pulmonary metastases. Next, we retrospectively reviewed autopsy records of 60 Japanese patients who died of hormone-refractory metastatic PCa with particular focus upon metastatic profiles. A comparative study of stage D 2 patients with (n ¼ 20) and without (n ¼ 77) pulmonary metastases found no significant differences in EOD score, performance status, marker response and survival. Only tumor grade was better in the group with, than without pulmonary metastases (P ¼ 0.0120, chi-square analysis). In the series of autopsies, we found pulmonary metastases in 38 cases (63%), following metastases of the bone (57 cases, 95%) and lymph nodes (52 cases, 87%). A retrospective analysis of survival showed that patients with bone or lymph node metastases had a positive relative risk. In contrast, lung metastasis could be a positive prognostic indicator, although the findings were not statistically significant. These data suggest that the presence of pulmonary metastasis has no ominous impact on clinical course and disease outcome even in patients with disseminated prostate cancer.

show abstract

“…Common primary sites of metastatic lesions in the brain include the lung, breast and gastrointestinal tract [4,5], The incidence of metastasis of prostatic carci noma in the brain is 2.4% in large series of studies [6,7], According to the literature, the prognosis of prostatic carcinoma with metastases to the brain is poor [8], Espe cially, patients treated only with endocrine or irradiation therapy, not combined with resection of the brain tumor, may survive only for a short period of time.…”

Section: Discussionmentioning

confidence: 99%

Effect of Endocrine Therapy on a Brain Metastatic Lesion of Prostatic Carcinoma

Kohri¹,

Yamate²,

Tsujihashi³

et al. 1991

Urol Int

View full text Add to dashboard Cite

We describe a 62-year-old male with brain metastasis from prostatic carcinoma, which regressed with medical and surgical endocrine therapies. The patient’s presenting complaints were left periocular and deep ocular pain and a defect of the left visual field. During treatment of the above symptoms, macrohematuria, dysuria and pollakiuria occurred. Pathological examination of a transrectal needle biopsy disclosed moderately differentiated adenocarcinoma of the prostate. Computerized tomographic scan (CT) and magnetic resonance imaging demonstrated a brain tumor at the frontal skull base and the region of the frontal lobe suspected to be a metastasis of the prostatic carcinoma. One week after a period of daily administration of estramustine phosphate sodium, the prostate was observed to be softened and slightly decreased in size. The visual field defect and disturbance of urination gradually improved. The prostate decreased to normal size and no tumor mass could be detected on the brain CT after 3 months of treatment.

show abstract

Lung metastases in prostatic carcinoma

Cited by 76 publications

References 9 publications

An assessment of bone scans for monitoring osseous metastases in patients being treated for prostate carcinoma

An assessment of bone scans for monitoring osseous metastases in patients being treated for prostate carcinoma

Clinical significance of pulmonary metastases in stage D2 prostate cancer patients

Effect of Endocrine Therapy on a Brain Metastatic Lesion of Prostatic Carcinoma

Contact Info

Product

Resources

About